Literature DB >> 21475253

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.

J Asano1, A Nakano, A Oda, H Amou, M Hiasa, K Takeuchi, H Miki, S Nakamura, T Harada, S Fujii, K Kagawa, I Endo, K Yata, A Sakai, S Ozaki, T Matsumoto, M Abe.   

Abstract

Bone marrow stromal cells (BMSCs) and osteoclasts (OCs) confer multiple myeloma (MM) cell survival through elaborating factors. We demonstrate herein that IL-6 and TNF family cytokines, TNFα, BAFF and APRIL, but not IGF-1 cooperatively enhance the expression of the serine/threonine kinase Pim-2 in MM cells. BMSCs and OCs upregulate Pim-2 expression in MM cells largely via the IL-6/STAT3 and NF-κB pathway, respectively. Pim-2 short interfering RNA reduces MM cell viability in cocultures with BMSCs or OCs. Thus, upregulation of Pim-2 appears to be a novel anti-apoptotic mechanism for MM cell survival. Interestingly, the mammalian target of rapamycin inhibitor rapamycin further suppresses the MM cell viability in combination with the Pim-2 silencing. The Pim inhibitor (Z)-5-(4-propoxybenzylidene) thiazolidine-2, 4-dione and the PI3K inhibitor LY294002 cooperatively enhance MM cell death. The Pim inhibitor suppresses 4E-BP1 phosphorylation along with the reduction of Mcl-1 and c-Myc. Pim-2 may therefore become a new target for MM treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21475253     DOI: 10.1038/leu.2011.60

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  46 in total

Review 1.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 2.  4E-BP1, a multifactor regulated multifunctional protein.

Authors:  Xiaoyu Qin; Bin Jiang; Yanjie Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 3.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

4.  Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Authors:  Karin Jöhrer; Marlene Obkircher; Daniel Neureiter; Johanna Parteli; Claudia Zelle-Rieser; Eva Maizner; Johann Kern; Martin Hermann; Frank Hamacher; Olaf Merkel; Nathalie Wacht; Christian Zidorn; Marcel Scheideler; Richard Greil
Journal:  J Mol Med (Berl)       Date:  2011-12-29       Impact factor: 4.599

5.  TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

Authors:  Hirofumi Tenshin; Jumpei Teramachi; Asuka Oda; Ryota Amachi; Masahiro Hiasa; Ariunzaya Bat-Erdene; Keiichiro Watanabe; Masami Iwasa; Takeshi Harada; Shiro Fujii; Kumiko Kagawa; Kimiko Sogabe; Shingen Nakamura; Hirokazu Miki; Kiyoe Kurahashi; Sumiko Yoshida; Kenichi Aihara; Itsuro Endo; Eiji Tanaka; Toshio Matsumoto; Masahiro Abe
Journal:  Blood Adv       Date:  2017-10-26

6.  Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.

Authors:  Jing Zheng; Yonggang Sha; Logan Roof; Oded Foreman; John Lazarchick; Jagadish Kummetha Venkta; Cleopatra Kozlowski; Cristina Gasparetto; Nelson Chao; Allen Ebens; Jianda Hu; Yubin Kang
Journal:  Cancer Lett       Date:  2018-10-09       Impact factor: 8.679

7.  Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.

Authors:  Ayako Nakano; Hirokazu Miki; Shingen Nakamura; Takeshi Harada; Asuka Oda; Hiroe Amou; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

8.  Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.

Authors:  M Hiasa; J Teramachi; A Oda; R Amachi; T Harada; S Nakamura; H Miki; S Fujii; K Kagawa; K Watanabe; I Endo; Y Kuroda; T Yoneda; D Tsuji; M Nakao; E Tanaka; K Hamada; S Sano; K Itoh; T Matsumoto; M Abe
Journal:  Leukemia       Date:  2014-05-02       Impact factor: 11.528

Review 9.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

10.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Authors:  Erika K Keeton; Kristen McEachern; Keith S Dillman; Sangeetha Palakurthi; Yichen Cao; Michael R Grondine; Surinder Kaur; Suping Wang; Yuching Chen; Allan Wu; Minhui Shen; Francis D Gibbons; Michelle L Lamb; Xiaolan Zheng; Richard M Stone; Daniel J Deangelo; Leonidas C Platanias; Les A Dakin; Huawei Chen; Paul D Lyne; Dennis Huszar
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.